Medpace (MEDP) Financials

$293.03 -2.74 (-0.93%)

Closing price 05/22/2025 04:00 PM Eastern

Extended Trading

$292.98 -0.04 (-0.02%)

As of 05/22/2025 04:08 PM Eastern

Annual Income Statements for Medpace

This table shows Medpace's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	404	283	245	182	145	100	73	39	13	-8.67
Consolidated Net Income / (Loss)	404	283	245	182	145	100	73	39	13	-8.67
Net Income / (Loss) Continuing Operations	404	283	245	182	145	100	73	39	13	-8.67
Total Pre-Tax Income	476	336	283	202	169	125	94	57	22	-7.83
Total Operating Income	447	337	279	199	167	127	101	65	52	21
Total Gross Profit	2,109	1,886	1,460	1,142	926	861	216	224	371	320
Total Revenue	2,109	1,886	1,460	1,142	926	861	705	436	422	359
Operating Revenue	2,109	1,886	1,460	1,142	926	861	705	436	422	359
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	489	212	51	39
Total Operating Expenses	1,662	1,549	1,181	944	759	734	114	160	318	300
Selling, General & Admin Expense	180	161	131	108	92	95	76	63	62	57
Depreciation Expense	28	24	19	16	12	8.36	9.24	8.57	7.44	6.38
Amortization Expense	1.44	2.20	3.35	5.11	7.88	15	30	38	51	63
Other Operating Expenses / (Income)	1,453	1,361	1,028	814	647	615	-	50	199	164
Total Other Income / (Expense), net	29	-1.14	4.16	3.24	1.49	-2.43	-7.10	-7.91	-31	-28
Interest & Investment Income	25	-0.49	-2.91	-0.11	0.31	-1.57	-8.16	-7.56	-19	-27
Other Income / (Expense), net	4.06	-0.66	7.07	3.34	1.18	-0.86	1.06	-0.35	-0.42	-1.13
Income Tax Expense	72	53	37	20	23	24	21	18	8.53	0.84
Basic Earnings per Share	$13.06	$9.20	$7.57	$5.06	$4.07	$2.79	$2.05	$1.00	$0.38	($0.28)
Weighted Average Basic Shares Outstanding	30.96M	30.72M	32.39M	35.86M	35.64M	35.88M	35.55M	39.06M	35.69M	31.35M
Diluted Earnings per Share	$12.63	$8.88	$7.28	$4.81	$3.84	$2.67	$1.97	$0.98	$0.37	($0.28)
Weighted Average Diluted Shares Outstanding	32.01M	31.84M	33.67M	37.70M	37.71M	37.58M	36.91M	39.84M	36.33M	31.35M
Weighted Average Basic & Diluted Shares Outstanding	30.47M	61.52M	31.05M	35.23M	35.73M	36.09M	35.70M	39.10M	35.30M	31M

This table shows Medpace's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	115	117	96	88	103	78	71	61	73	69	66
Consolidated Net Income / (Loss)	115	117	96	88	103	78	71	61	73	69	66
Net Income / (Loss) Continuing Operations	115	117	96	88	103	78	71	61	73	69	66
Total Pre-Tax Income	118	134	119	110	113	91	83	76	86	74	82
Total Operating Income	114	125	112	105	104	87	85	78	86	76	78
Total Gross Profit	559	537	533	528	511	498	492	461	434	394	384
Total Revenue	559	537	533	528	511	498	492	461	434	394	384
Operating Revenue	559	537	533	528	511	498	492	461	434	394	384
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	445	411	421	423	407	411	408	382	348	318	306
Selling, General & Admin Expense	58	45	49	41	44	43	41	39	38	33	35
Depreciation Expense	6.69	7.15	7.16	6.87	6.63	6.42	6.33	5.97	5.41	5.06	4.95
Amortization Expense	0.24	0.36	0.36	0.36	0.36	0.55	0.55	0.55	0.55	0.84	0.84
Other Operating Expenses / (Income)	380	358	364	374	356	362	359	337	304	278	265
Total Other Income / (Expense), net	4.65	8.50	6.50	5.33	8.71	3.39	-1.71	-2.65	-0.17	-2.79	4.07
Interest & Investment Income	6.46	7.88	7.53	5.47	4.12	1.84	-0.11	-1.37	-0.86	-0.83	-1.58
Other Income / (Expense), net	-1.82	0.62	-1.03	-0.13	4.59	1.54	-1.60	-1.28	0.69	-1.96	5.65
Income Tax Expense	3.58	17	22	22	10	12	13	15	13	4.98	16
Basic Earnings per Share	$3.77	$3.78	$3.11	$2.85	$3.32	$2.55	$2.30	$2.00	$2.35	$2.17	$2.13
Weighted Average Basic Shares Outstanding	30.39M	30.96M	31.05M	30.99M	30.84M	30.72M	30.63M	30.54M	31.01M	32.39M	31.01M
Diluted Earnings per Share	$3.67	$3.67	$3.01	$2.75	$3.20	$2.46	$2.22	$1.93	$2.27	$2.08	$2.05
Weighted Average Diluted Shares Outstanding	31.20M	32.01M	32.09M	32.09M	32.00M	31.84M	31.76M	31.58M	32.16M	33.67M	32.25M
Weighted Average Basic & Diluted Shares Outstanding	28.74M	30.47M	31.08M	31.00M	30.98M	61.52M	61.37M	30.56M	30.50M	31.05M	31.10M

This table details how cash moves in and out of Medpace's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	424	217	-433	184	146	109	-3.21	-11	20	-38
Net Cash From Operating Activities	609	433	388	263	259	202	157	97	92	86
Net Cash From Continuing Operating Activities	609	433	388	263	259	202	157	97	92	86
Net Income / (Loss) Continuing Operations	404	283	245	182	145	100	73	39	13	-8.67
Consolidated Net Income / (Loss)	404	283	245	182	145	100	73	39	13	-8.67
Depreciation Expense	28	24	19	16	12	8.36	9.24	8.57	7.44	6.38
Amortization Expense	25	2.20	3.35	5.11	7.17	15	22	30	53	66
Non-Cash Adjustments To Reconcile Net Income	-5.13	43	155	104	80	32	44	17	40	41
Changes in Operating Assets and Liabilities, net	157	81	-35	-44	15	46	7.95	3.09	-22	-19
Net Cash From Investing Activities	-28	-35	-39	-31	-31	-19	-17	-12	-13	-6.43
Net Cash From Continuing Investing Activities	-28	-35	-39	-31	-31	-19	-17	-12	-13	-6.43
Purchase of Property, Plant & Equipment	-37	-37	-37	-28	-31	-18	-16	-12	-14	-6.47
Other Investing Activities, net	8.24	2.02	-1.86	-3.09	0.13	-1.23	-0.95	0.06	0.12	0.03
Net Cash From Financing Activities	-154	-183	-776	-44	-82	-74	-142	-98	-58	-116
Net Cash From Continuing Financing Activities	-154	-183	-776	-44	-82	-74	-142	-98	-58	-116
Repayment of Debt	0.00	-155	-274	0.00	0.00	-80	-144	-44	-394	-117
Repurchase of Common Equity	-170	-144	-848	-62	-98	0.00	0.00	-156	-2.72	0.00
Issuance of Debt	0.00	105	324	0.00	0.00	-	-	100	165	0.00
Other Financing Activities, net	16	11	22	18	16	6.52	2.49	1.81	0.56	0.25
Effect of Exchange Rate Changes	-2.51	1.08	-	-	-	-0.17	-	-	-	-0.60
Cash Interest Paid	0.17	3.06	2.94	0.12	0.10	1.49	7.59	6.89	17	24
Cash Income Taxes Paid	84	76	50	56	23	13	23	17	18	11

This table details how cash moves in and out of Medpace's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-228	13	146	104	162	150	56	-7.78	19	-2.74	-12
Net Cash From Operating Activities	126	191	149	116	153	156	114	83	80	137	108
Net Cash From Continuing Operating Activities	126	191	149	116	153	156	114	83	80	137	108
Net Income / (Loss) Continuing Operations	115	117	96	88	103	78	71	61	73	69	66
Consolidated Net Income / (Loss)	115	117	96	88	103	78	71	61	73	69	66
Depreciation Expense	6.69	7.15	7.16	6.87	6.63	6.42	6.33	5.97	5.41	5.06	4.95
Amortization Expense	0.24	6.18	18	0.36	0.36	0.55	0.55	0.55	0.55	0.84	0.84
Non-Cash Adjustments To Reconcile Net Income	24	-18	-70	20	63	12	12	10	8.74	64	16
Changes in Operating Assets and Liabilities, net	-20	79	97	0.44	-20	59	25	4.57	-7.52	-2.19	21
Net Cash From Investing Activities	-9.99	-7.56	-10	-13	2.53	-8.00	-8.66	-8.47	-9.50	-9.22	-7.19
Net Cash From Continuing Investing Activities	-9.99	-7.56	-10	-13	2.53	-8.00	-8.66	-8.47	-9.50	-9.22	-7.19
Purchase of Property, Plant & Equipment	-9.99	-7.64	-11	-13	-5.50	-9.99	-8.70	-8.45	-9.51	-9.24	-7.18
Other Investing Activities, net	0.01	0.08	0.05	0.08	8.03	1.99	0.04	-0.02	0.01	0.02	-0.01
Net Cash From Financing Activities	-346	-169	6.27	0.67	7.66	1.52	-49	-82	-53	-131	-109
Net Cash From Continuing Financing Activities	-346	-169	6.27	0.67	7.66	1.52	-49	-82	-53	-131	-109
Repurchase of Common Equity	-372	-170	-	-	0.00	-	-	-24	-120	-47	-
Other Financing Activities, net	26	1.26	6.27	0.67	7.66	1.52	5.73	1.66	2.46	5.76	0.89
Other Net Changes in Cash	2.12	-	-	-0.39	-1.31	-	-	-	-	0.92	-3.74

This table presents Medpace's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	1/1/2019	12/31/2017	12/31/2016	12/31/2015
Total Assets	2,101	1,657	1,352	1,660	1,391	1,143	1,005	951	979	984
Total Current Assets	1,029	594	334	691	474	317	178	130	133	95
Cash & Equivalents	669	245	28	461	278	132	0.00	26	37	15
Accounts Receivable	296	298	253	186	161	156	0.00	83	80	65
Prepaid Expenses	63	50	52	43	35	29	21	20	16	12
Plant, Property, & Equipment, net	124	121	110	93	85	47	38	49	44	38
Total Noncurrent Assets	948	942	909	876	832	779	52	772	802	852
Goodwill	662	662	662	662	662	662	0.00	661	661	661
Intangible Assets	34	36	38	41	46	54	0.00	99	136	187
Noncurrent Deferred & Refundable Income Taxes	100	74	48	25	0.54	0.38	0.00	6.34	0.10	0.16
Other Noncurrent Operating Assets	151	170	160	147	123	62	52	5.94	4.90	3.93
Total Liabilities & Shareholders' Equity	2,101	1,657	1,352	1,660	1,391	1,143	1,005	951	979	984
Total Liabilities	1,275	1,098	966	707	585	417	406	447	368	571
Total Current Liabilities	1,105	925	803	557	440	343	263	193	169	134
Accounts Payable	33	32	33	26	27	22	0.00	17	11	8.73
Accrued Expenses	308	293	210	159	134	109	0.00	24	24	20
Current Deferred Revenue	711	560	463	345	256	192	0.00	74	66	51
Other Current Liabilities	54	40	48	28	24	19	11	62	55	54
Total Noncurrent Liabilities	171	173	163	150	145	74	63	254	200	437
Noncurrent Deferred & Payable Income Tax Liabilities	1.80	2.40	1.07	1.08	14	13	3.16	0.56	12	21
Other Noncurrent Operating Liabilities	169	170	162	149	131	16	60	11	7.97	7.29
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	826	559	386	953	806	726	-32	504	611	413
Total Preferred & Common Equity	826	559	386	953	806	726	599	504	611	413
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	826	559	386	953	806	726	-32	504	611	413
Common Stock	844	803	771	728	696	667	0.00	631	624	439
Retained Earnings	8.17	-222	-360	235	115	68	-32	-120	-9.58	-23
Treasury Stock	-12	-12	-12	-5.43	-5.58	-6.03	0.00	-6.03	0.00	-
Accumulated Other Comprehensive Income / (Loss)	-15	-10	-12	-4.85	-0.13	-2.74	0.00	-0.73	-3.74	-2.56

This table presents Medpace's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,897	2,084	1,920	1,796	1,487	1,407	1,396	1,328
Total Current Assets	821	1,033	873	745	449	379	368	338
Cash & Equivalents	441	657	511	407	95	39	47	31
Accounts Receivable	298	311	301	279	293	275	258	249
Prepaid Expenses	82	64	61	59	61	65	63	58
Plant, Property, & Equipment, net	128	124	122	119	115	115	114	105
Total Noncurrent Assets	948	927	925	932	923	913	914	886
Goodwill	662	662	662	662	662	662	662	662
Intangible Assets	34	35	35	35	36	37	37	39
Noncurrent Deferred & Refundable Income Taxes	100	77	75	75	59	52	49	27
Other Noncurrent Operating Assets	151	154	152	159	165	162	165	158
Total Liabilities & Shareholders' Equity	1,897	2,084	1,920	1,796	1,487	1,407	1,396	1,328
Total Liabilities	1,304	1,203	1,156	1,124	1,016	1,016	1,048	979
Total Current Liabilities	1,122	1,041	993	957	849	852	882	821
Accounts Payable	61	26	27	24	29	34	37	28
Accrued Expenses	286	307	293	271	265	232	201	204
Current Deferred Revenue	719	671	638	617	519	491	466	418
Other Current Liabilities	56	37	35	45	36	41	63	31
Total Noncurrent Liabilities	181	161	163	168	167	163	167	158
Noncurrent Deferred & Payable Income Tax Liabilities	1.84	2.29	2.29	2.36	1.13	1.10	1.09	0.91
Other Noncurrent Operating Liabilities	180	159	161	165	166	162	165	157
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	594	881	764	672	471	391	347	350
Total Preferred & Common Equity	594	881	764	672	471	391	347	350
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	594	881	764	672	471	391	347	350
Common Stock	887	837	819	815	796	786	779	760
Retained Earnings	-270	66	-31	-119	-300	-371	-408	-380
Treasury Stock	-12	-12	-12	-12	-12	-12	-12	-14
Accumulated Other Comprehensive Income / (Loss)	-12	-9.18	-13	-12	-13	-11	-11	-16

This table displays calculated financial ratios and metrics derived from Medpace's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.84%	29.17%	27.80%	23.38%	7.54%	22.19%	61.55%	3.46%	17.41%	0.00%
EBITDA Growth	38.84%	17.65%	38.12%	19.26%	24.91%	11.90%	30.09%	-8.78%	23.05%	0.00%
EBIT Growth	34.14%	17.64%	41.50%	20.05%	33.09%	23.79%	58.30%	23.89%	167.99%	0.00%
NOPAT Growth	33.80%	17.38%	35.11%	24.17%	40.72%	30.09%	76.65%	38.84%	122.97%	0.00%
Net Income Growth	42.99%	15.26%	34.93%	25.08%	44.74%	37.25%	87.07%	191.41%	254.79%	0.00%
EPS Growth	42.23%	21.98%	51.35%	25.26%	43.82%	35.53%	101.02%	164.86%	232.14%	0.00%
Operating Cash Flow Growth	40.48%	11.68%	47.36%	1.80%	28.14%	28.92%	60.79%	6.16%	6.83%	0.00%
Free Cash Flow Firm Growth	41.94%	16.34%	51.06%	-15.78%	151.06%	-165.24%	805.31%	20.13%	0.00%	0.00%
Invested Capital Growth	-50.20%	-23.18%	-16.98%	-6.89%	-17.44%	1,654.81%	-94.97%	-5.25%	-4.79%	0.00%
Revenue Q/Q Growth	1.84%	5.85%	6.22%	4.47%	3.32%	4.59%	12.71%	1.03%	0.00%	0.00%
EBITDA Q/Q Growth	9.46%	4.46%	6.37%	1.09%	11.02%	0.22%	19.57%	-9.07%	0.00%	0.00%
EBIT Q/Q Growth	8.97%	4.47%	6.93%	0.60%	12.66%	4.04%	17.48%	3.10%	0.00%	0.00%
NOPAT Q/Q Growth	9.92%	1.55%	9.95%	-1.12%	17.37%	6.16%	16.38%	11.85%	0.00%	0.00%
Net Income Q/Q Growth	10.59%	3.52%	8.22%	-0.46%	16.93%	7.55%	18.59%	40.68%	0.00%	0.00%
EPS Q/Q Growth	10.60%	4.47%	11.66%	-0.62%	16.72%	8.10%	17.96%	48.48%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	5.96%	4.77%	20.42%	-11.61%	23.11%	9.49%	7.40%	-0.42%	0.67%	0.00%
Free Cash Flow Firm Q/Q Growth	8.15%	4.43%	24.62%	-40.90%	159.70%	-533.22%	501.96%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-30.48%	-16.56%	-11.00%	-1.62%	-22.70%	-2.91%	-94.62%	-1.69%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	30.59%	51.45%	87.91%	89.15%
EBITDA Margin	23.86%	19.22%	21.10%	19.53%	20.20%	17.39%	18.99%	23.58%	26.75%	25.52%
Operating Margin	21.19%	17.86%	19.09%	17.39%	18.04%	14.78%	14.34%	14.87%	12.45%	5.73%
EBIT Margin	21.38%	17.83%	19.57%	17.68%	18.17%	14.68%	14.49%	14.79%	12.35%	5.41%
Profit (Net Income) Margin	19.17%	15.00%	16.81%	15.92%	15.70%	11.67%	10.39%	8.97%	3.18%	-2.42%
Tax Burden Percent	84.97%	84.25%	86.75%	90.09%	86.26%	80.46%	77.90%	68.70%	61.14%	110.77%
Interest Burden Percent	105.54%	99.85%	98.98%	99.95%	100.18%	98.76%	92.01%	88.28%	42.17%	-40.30%
Effective Tax Rate	15.03%	15.75%	13.25%	9.91%	13.74%	19.54%	22.10%	31.30%	38.86%	0.00%
Return on Invested Capital (ROIC)	161.71%	78.65%	53.74%	35.10%	24.68%	30.29%	20.67%	5.98%	4.09%	1.79%
ROIC Less NNEP Spread (ROIC-NNEP)	156.31%	79.51%	52.10%	34.31%	23.98%	52.12%	16.86%	3.09%	-2.76%	-4.12%
Return on Net Nonoperating Assets (RNNOA)	-103.29%	-18.82%	-17.10%	-14.42%	-5.70%	-1.35%	10.40%	1.04%	-1.47%	-3.89%
Return on Equity (ROE)	58.42%	59.83%	36.64%	20.68%	18.98%	28.95%	31.06%	7.02%	2.62%	-2.10%
Cash Return on Invested Capital (CROIC)	228.74%	104.87%	72.30%	42.23%	43.79%	-148.14%	201.53%	11.37%	8.99%	0.00%
Operating Return on Assets (OROA)	24.00%	22.34%	18.97%	13.24%	13.28%	11.77%	10.44%	6.69%	5.30%	1.97%
Return on Assets (ROA)	21.52%	18.80%	16.29%	11.92%	11.48%	9.35%	7.49%	4.05%	1.37%	-0.88%
Return on Common Equity (ROCE)	58.42%	59.83%	36.64%	20.68%	18.98%	28.95%	31.06%	7.02%	2.62%	-2.10%
Return on Equity Simple (ROE_SIMPLE)	48.98%	50.60%	63.50%	19.08%	18.04%	13.83%	12.22%	7.77%	2.20%	-2.10%
Net Operating Profit after Tax (NOPAT)	380	284	242	179	144	102	79	45	32	14
NOPAT Margin	18.00%	15.05%	16.56%	15.66%	15.56%	11.89%	11.17%	10.22%	7.61%	4.01%
Net Nonoperating Expense Percent (NNEP)	5.40%	-0.86%	1.64%	0.79%	0.71%	-21.82%	3.81%	2.89%	6.85%	5.91%
Return On Investment Capital (ROIC_SIMPLE)	45.99%	50.77%	55.40%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	69.41%	48.55%	12.09%	10.85%
SG&A Expenses to Revenue	8.54%	8.56%	9.00%	9.49%	9.95%	11.06%	10.74%	14.53%	14.59%	15.87%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	78.81%	82.14%	80.91%	82.61%	81.96%	85.22%	16.25%	36.57%	75.46%	83.42%
Earnings before Interest and Taxes (EBIT)	451	336	286	202	168	126	102	65	52	19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	503	362	308	223	187	150	134	103	113	92
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	12.51	16.83	17.10	8.21	6.18	4.17	0.00	2.71	2.41	0.00
Price to Tangible Book Value (P/TBV)	80.18	0.00	0.00	31.39	51.38	317.58	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.90	4.99	4.52	6.85	5.38	3.52	2.67	3.13	3.48	0.00
Price to Earnings (P/E)	25.54	33.26	26.92	43.01	34.25	30.15	25.75	34.86	109.41	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.92%	3.01%	3.71%	2.32%	2.92%	3.32%	3.88%	2.87%	0.91%	0.00%
Enterprise Value to Invested Capital (EV/IC)	61.86	29.22	16.24	14.97	8.90	4.60	51.71	2.19	2.12	0.00
Enterprise Value to Revenue (EV/Rev)	4.58	4.86	4.54	6.44	5.08	3.42	2.67	3.63	3.85	0.00
Enterprise Value to EBITDA (EV/EBITDA)	19.19	25.27	21.51	33.00	25.14	19.65	14.08	15.41	14.40	0.00
Enterprise Value to EBIT (EV/EBIT)	21.42	27.25	23.19	36.45	27.95	23.28	18.46	24.58	31.18	0.00
Enterprise Value to NOPAT (EV/NOPAT)	25.43	32.28	27.41	41.14	32.63	28.73	23.94	35.58	50.59	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	15.86	21.14	17.08	27.95	18.18	14.57	12.04	16.28	17.70	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	17.98	24.21	20.38	34.18	18.39	0.00	2.46	18.70	23.01	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.13	0.00	0.00	0.06	0.00	0.49	0.31	0.99
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.06	0.00	0.46	0.29	0.99
Financial Leverage	-0.66	-0.24	-0.33	-0.42	-0.24	-0.03	0.62	0.34	0.53	0.94
Leverage Ratio	2.71	3.18	2.25	1.73	1.65	3.10	4.15	1.73	1.92	2.38
Compound Leverage Factor	2.86	3.18	2.23	1.73	1.66	3.06	3.82	1.53	0.81	-0.96
Debt to Total Capital	0.00%	0.00%	11.46%	0.00%	0.00%	5.86%	0.00%	33.02%	23.94%	49.68%
Short-Term Debt to Total Capital	0.00%	0.00%	11.46%	0.00%	0.00%	0.00%	0.00%	2.19%	1.54%	0.01%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	5.86%	0.00%	30.82%	22.39%	49.67%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	88.54%	100.00%	100.00%	94.14%	100.00%	66.98%	76.07%	50.32%
Debt to EBITDA	0.00	0.00	0.16	0.00	0.00	0.30	0.00	2.41	1.70	4.45
Net Debt to EBITDA	0.00	0.00	0.07	0.00	0.00	-0.58	0.00	2.16	1.37	4.26
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.30	0.00	2.25	1.59	4.45
Debt to NOPAT	0.00	0.00	0.21	0.00	0.00	0.44	0.00	5.57	5.99	28.36
Net Debt to NOPAT	0.00	0.00	0.09	0.00	0.00	-0.85	0.00	4.98	4.82	27.13
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.44	0.00	5.20	5.60	28.36
Altman Z-Score	6.53	6.52	5.09	8.02	6.32	5.53	3.68	2.26	2.94	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.93	0.64	0.42	1.24	1.08	0.92	0.68	0.67	0.79	0.71
Quick Ratio	0.87	0.59	0.35	1.16	1.00	0.84	0.00	0.57	0.69	0.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	537	378	325	215	256	-501	768	85	71	0.00
Operating Cash Flow to CapEx	1,665.80%	1,182.53%	1,052.22%	931.44%	825.39%	1,126.99%	977.18%	830.65%	677.64%	1,328.23%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.58	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.55	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.29	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.12	1.25	0.97	0.75	0.73	0.80	0.72	0.45	0.43	0.36
Accounts Receivable Turnover	7.09	6.84	6.64	6.58	5.85	0.00	0.00	5.36	5.82	5.52
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	17.27	16.37	14.38	12.82	14.00	20.28	16.32	9.43	10.37	9.57
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.35	5.19	4.46
Days Sales Outstanding (DSO)	51.47	53.40	54.98	55.50	62.41	0.00	0.00	68.14	62.71	66.16
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23.77	70.33	81.77
Cash Conversion Cycle (CCC)	51.47	53.40	54.98	55.50	62.41	0.00	0.00	44.37	-7.62	-15.61
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	156	314	408	492	528	640	36	725	765	804
Invested Capital Turnover	8.98	5.23	3.25	2.24	1.59	2.55	1.85	0.59	0.54	0.45
Increase / (Decrease) in Invested Capital	-157	-95	-84	-36	-112	603	-689	-40	-38	0.00
Enterprise Value (EV)	9,657	9,160	6,628	7,361	4,702	2,942	1,885	1,585	1,624	0.00
Market Capitalization	10,326	9,405	6,606	7,822	4,979	3,029	1,885	1,364	1,469	0.00
Book Value per Share	$26.56	$18.22	$12.42	$26.52	$22.53	$20.16	($0.91)	$13.39	$15.00	$13.19
Tangible Book Value per Share	$4.14	($4.54)	($10.10)	$6.93	$2.71	$0.26	($0.91)	($6.81)	($4.58)	($13.85)
Total Capital	826	559	436	953	806	771	-32	752	803	822
Total Debt	0.00	0.00	50	0.00	0.00	45	0.00	248	192	408
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	45	0.00	232	180	408
Net Debt	-669	-245	22	-461	-278	-87	0.00	222	155	390
Capital Expenditures (CapEx)	37	37	37	28	31	18	16	12	14	6.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-745	-577	-448	-328	-244	-158	-85	-73	-60	-57
Debt-free Net Working Capital (DFNWC)	-75	-331	-420	134	34	-26	-85	-46	-23	-39
Net Working Capital (NWC)	-75	-331	-470	134	34	-26	-85	-63	-35	-39
Net Nonoperating Expense (NNE)	-25	0.96	-3.61	-2.92	-1.29	1.96	5.53	5.44	19	23
Net Nonoperating Obligations (NNO)	-669	-245	22	-461	-278	-87	69	222	155	390
Total Depreciation and Amortization (D&A)	52	26	22	21	19	23	32	38	61	72
Debt-free, Cash-free Net Working Capital to Revenue	-35.31%	-30.58%	-30.67%	-28.68%	-26.38%	-18.34%	-12.12%	-16.67%	-14.32%	-15.87%
Debt-free Net Working Capital to Revenue	-3.57%	-17.57%	-28.73%	11.70%	3.62%	-3.02%	-12.12%	-10.60%	-5.45%	-10.93%
Net Working Capital to Revenue	-3.57%	-17.57%	-32.16%	11.70%	3.62%	-3.02%	-12.12%	-14.38%	-8.39%	-10.94%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$13.06	$9.20	$7.57	$5.06	$4.07	$2.79	$2.05	$1.00	$0.38	$0.00
Adjusted Weighted Average Basic Shares Outstanding	30.96M	30.72M	32.39M	35.86M	35.64M	35.88M	35.55M	39.06M	35.69M	0.00
Adjusted Diluted Earnings per Share	$12.63	$8.88	$7.28	$4.81	$3.84	$2.67	$1.97	$0.98	$0.37	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	32.01M	31.84M	33.67M	37.70M	37.71M	37.58M	36.91M	39.84M	36.33M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.47M	61.52M	31.05M	35.23M	35.73M	36.09M	35.69M	35.48M	40.73M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	380	284	242	179	144	102	79	45	32	21
Normalized NOPAT Margin	18.00%	15.05%	16.56%	15.66%	15.56%	11.89%	11.17%	10.22%	7.61%	5.82%
Pre Tax Income Margin	22.57%	17.80%	19.37%	17.67%	18.20%	14.50%	13.33%	13.06%	5.21%	-2.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.85	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.99	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.59	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.73	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	42.01%	50.92%	345.54%	34.15%	67.60%	0.00%	0.00%	397.69%	20.25%	0.00%

This table displays calculated financial ratios and metrics derived from Medpace's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.30%	7.66%	8.29%	14.59%	17.73%	26.47%	28.34%	31.22%	31.16%	27.73%	29.83%
EBITDA Growth	2.58%	45.38%	50.88%	34.22%	24.56%	19.24%	1.03%	22.82%	31.93%	29.82%	48.91%
EBIT Growth	2.80%	41.79%	33.54%	36.19%	25.06%	19.32%	-0.20%	23.28%	33.13%	33.12%	52.39%
NOPAT Growth	16.29%	45.39%	26.60%	33.04%	29.60%	5.76%	14.74%	31.79%	21.21%	45.21%	31.64%
Net Income Growth	11.70%	49.45%	36.68%	44.68%	40.74%	14.02%	6.85%	23.72%	18.89%	37.25%	35.93%
EPS Growth	14.69%	49.19%	35.59%	42.49%	40.97%	18.27%	8.29%	32.19%	34.32%	57.58%	58.91%
Operating Cash Flow Growth	-17.58%	21.91%	30.33%	41.06%	90.67%	14.42%	5.43%	-14.59%	73.11%	92.80%	49.95%
Free Cash Flow Firm Growth	-9.38%	57.05%	56.46%	62.46%	36.47%	9.84%	49.10%	-19.97%	0.89%	81.08%	-55.04%
Invested Capital Growth	-42.47%	-50.20%	-40.24%	-37.90%	-36.31%	-23.18%	-18.07%	-17.02%	-20.46%	-16.98%	-8.23%
Revenue Q/Q Growth	4.10%	0.61%	0.99%	3.34%	2.54%	1.20%	6.86%	6.17%	10.14%	2.70%	9.26%
EBITDA Q/Q Growth	-14.85%	2.39%	21.22%	-2.94%	20.68%	6.27%	7.84%	-9.93%	15.53%	-9.96%	31.09%
EBIT Q/Q Growth	-11.34%	13.26%	5.93%	-3.35%	22.28%	6.67%	8.04%	-11.26%	16.68%	-10.79%	33.46%
NOPAT Q/Q Growth	0.46%	20.23%	8.40%	-11.17%	25.59%	4.69%	13.91%	-13.47%	2.49%	13.58%	30.85%
Net Income Q/Q Growth	-2.07%	21.36%	9.14%	-13.88%	31.03%	10.98%	15.53%	-16.22%	6.15%	4.00%	33.77%
EPS Q/Q Growth	0.00%	21.93%	9.45%	-14.06%	30.08%	10.81%	15.03%	-14.98%	9.13%	1.46%	40.41%
Operating Cash Flow Q/Q Growth	-34.00%	27.90%	28.07%	-23.76%	-2.38%	36.73%	38.62%	3.05%	-41.42%	25.99%	12.29%
Free Cash Flow Firm Q/Q Growth	-16.68%	10.18%	1.68%	-2.92%	44.40%	9.77%	5.58%	-18.45%	16.22%	49.00%	-43.33%
Invested Capital Q/Q Growth	-2.52%	-30.48%	-11.15%	-4.47%	-15.62%	-16.56%	-7.67%	-2.03%	1.77%	-11.00%	-6.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	21.24%	25.96%	25.51%	21.26%	22.63%	19.23%	18.31%	18.15%	21.39%	20.39%	23.26%
Operating Margin	20.32%	23.37%	21.05%	19.91%	20.36%	17.52%	17.24%	17.01%	19.86%	19.39%	20.28%
EBIT Margin	20.00%	23.48%	20.86%	19.89%	21.26%	17.83%	16.92%	16.73%	20.02%	18.90%	21.75%
Profit (Net Income) Margin	20.52%	21.81%	18.08%	16.73%	20.07%	15.71%	14.32%	13.25%	16.79%	17.42%	17.21%
Tax Burden Percent	96.97%	87.40%	81.18%	79.97%	90.96%	86.32%	84.79%	80.62%	84.73%	93.24%	80.63%
Interest Burden Percent	105.79%	106.26%	106.77%	105.20%	103.79%	102.08%	99.87%	98.23%	99.01%	98.89%	98.10%
Effective Tax Rate	3.03%	12.60%	18.82%	20.03%	9.04%	13.68%	15.21%	19.38%	15.27%	6.76%	19.37%
Return on Invested Capital (ROIC)	204.00%	183.44%	117.93%	98.00%	106.96%	79.04%	62.43%	51.13%	56.11%	58.69%	46.91%
ROIC Less NNEP Spread (ROIC-NNEP)	202.94%	181.81%	116.52%	96.28%	102.28%	76.43%	40.97%	49.22%	58.11%	59.87%	44.64%
Return on Net Nonoperating Assets (RNNOA)	-136.10%	-120.14%	-64.80%	-41.28%	-34.03%	-18.09%	0.67%	16.28%	-0.90%	-19.65%	-10.36%
Return on Equity (ROE)	67.90%	63.29%	53.12%	56.73%	72.93%	60.96%	63.11%	67.41%	55.21%	39.04%	36.54%
Cash Return on Invested Capital (CROIC)	243.40%	228.74%	165.47%	145.70%	134.33%	104.87%	86.86%	78.78%	77.09%	72.30%	54.47%
Operating Return on Assets (OROA)	23.36%	26.36%	24.20%	24.27%	26.15%	22.35%	21.41%	20.56%	22.84%	18.32%	20.58%
Return on Assets (ROA)	23.96%	24.48%	20.97%	20.42%	24.69%	19.69%	18.13%	16.28%	19.16%	16.89%	16.28%
Return on Common Equity (ROCE)	67.90%	63.29%	53.12%	56.73%	72.93%	60.96%	63.11%	67.41%	55.21%	39.04%	36.54%
Return on Equity Simple (ROE_SIMPLE)	70.15%	0.00%	41.49%	44.50%	46.54%	0.00%	58.01%	68.70%	73.99%	0.00%	64.80%
Net Operating Profit after Tax (NOPAT)	110	110	91	84	95	75	72	63	73	71	63
NOPAT Margin	19.71%	20.42%	17.09%	15.92%	18.52%	15.12%	14.62%	13.71%	16.83%	18.08%	16.35%
Net Nonoperating Expense Percent (NNEP)	1.06%	1.62%	1.40%	1.72%	4.68%	2.61%	21.47%	1.92%	-2.00%	-1.18%	2.26%
Return On Investment Capital (ROIC_SIMPLE)	18.55%	13.27%	-	-	-	13.49%	-	-	-	16.33%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	10.37%	8.47%	9.23%	7.85%	8.63%	8.53%	8.41%	8.55%	8.76%	8.48%	9.23%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	79.68%	76.63%	78.95%	80.09%	79.64%	82.48%	82.76%	82.99%	80.14%	80.61%	79.72%
Earnings before Interest and Taxes (EBIT)	112	126	111	105	109	89	83	77	87	74	83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	119	139	136	112	116	96	90	84	93	80	89
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	15.64	12.51	11.74	16.71	18.47	16.83	15.71	18.73	16.81	17.10	13.92
Price to Tangible Book Value (P/TBV)	0.00	80.18	56.14	193.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.30	4.90	5.00	6.29	6.32	4.99	4.15	4.38	3.74	4.52	3.54
Price to Earnings (P/E)	22.29	25.54	28.30	37.55	39.68	33.26	27.09	27.26	22.72	26.92	21.49
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.49%	3.92%	3.53%	2.66%	2.52%	3.01%	3.69%	3.67%	4.40%	3.71%	4.65%
Enterprise Value to Invested Capital (EV/IC)	58.10	61.86	43.16	48.47	45.34	29.22	19.44	18.04	14.22	16.24	10.86
Enterprise Value to Revenue (EV/Rev)	4.10	4.58	4.68	6.03	6.11	4.86	4.10	4.39	3.78	4.54	3.62
Enterprise Value to EBITDA (EV/EBITDA)	17.46	19.19	21.08	29.59	31.13	25.27	21.05	21.21	17.87	21.51	17.20
Enterprise Value to EBIT (EV/EBIT)	19.48	21.42	23.42	31.75	33.51	27.25	22.70	22.80	19.22	23.19	18.64
Enterprise Value to NOPAT (EV/NOPAT)	22.40	25.43	28.06	37.54	39.22	32.28	26.14	27.19	23.21	27.41	22.65
Enterprise Value to Operating Cash Flow (EV/OCF)	15.19	15.86	16.87	22.69	23.70	21.14	17.66	18.00	14.00	17.08	15.46
Enterprise Value to Free Cash Flow (EV/FCFF)	17.43	17.98	19.52	25.49	26.27	24.21	20.16	20.77	16.35	20.38	19.08
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.14	0.33	0.13	0.40
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.67	-0.66	-0.56	-0.43	-0.33	-0.24	0.02	0.33	-0.02	-0.33	-0.23
Leverage Ratio	2.92	2.71	2.64	2.88	3.13	3.18	3.43	4.04	2.88	2.25	2.33
Compound Leverage Factor	3.09	2.88	2.82	3.03	3.25	3.25	3.43	3.97	2.85	2.22	2.28
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12.33%	24.88%	11.46%	28.53%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12.33%	24.88%	11.46%	28.53%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	87.67%	75.12%	88.54%	71.47%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.35	0.16	0.48
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.21	0.07	0.38
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.45	0.21	0.64
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.27	0.09	0.49
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.21	6.02	6.37	7.76	7.68	6.03	5.15	4.92	3.82	4.57	3.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.73	0.93	0.99	0.88	0.78	0.64	0.53	0.44	0.42	0.42	0.41
Quick Ratio	0.66	0.87	0.93	0.82	0.72	0.59	0.46	0.37	0.35	0.35	0.34
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	222	267	242	238	245	170	155	147	180	155	104
Operating Cash Flow to CapEx	1,259.12%	2,494.65%	1,414.78%	904.34%	2,777.46%	1,566.14%	1,314.32%	977.01%	841.75%	1,478.78%	1,511.23%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.17	1.12	1.16	1.22	1.23	1.25	1.27	1.23	1.14	0.97	0.95
Accounts Receivable Turnover	7.47	7.09	6.85	7.05	7.31	6.84	6.58	6.68	6.48	6.64	6.31
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	17.47	17.27	17.34	17.12	16.89	16.37	16.23	15.32	14.73	14.38	14.29
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	48.86	51.47	53.25	51.80	49.92	53.40	55.51	54.63	56.33	54.98	57.82
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	48.86	51.47	53.25	51.80	49.92	53.40	55.51	54.63	56.33	54.98	57.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	152	156	225	253	265	314	376	407	415	408	459
Invested Capital Turnover	10.35	8.98	6.90	6.16	5.77	5.23	4.27	3.73	3.33	3.25	2.87
Increase / (Decrease) in Invested Capital	-112	-157	-151	-154	-151	-95	-83	-83	-107	-84	-41
Enterprise Value (EV)	8,841	9,657	9,691	12,250	11,994	9,160	7,305	7,341	5,907	6,628	4,981
Market Capitalization	9,283	10,326	10,348	12,761	12,401	9,405	7,400	7,325	5,839	6,606	4,872
Book Value per Share	$19.48	$26.56	$28.43	$24.65	$21.77	$18.22	$15.41	$12.82	$11.18	$12.42	$11.29
Tangible Book Value per Share	($3.38)	$4.14	$5.95	$2.13	($0.85)	($4.54)	($7.45)	($10.11)	($11.36)	($10.10)	($11.33)
Total Capital	594	826	881	764	672	559	471	446	462	436	490
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55	115	50	140
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-441	-669	-657	-511	-407	-245	-95	16	68	22	109
Capital Expenditures (CapEx)	9.99	7.64	11	13	5.50	9.99	8.70	8.45	9.51	9.24	7.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-742	-745	-666	-631	-619	-577	-495	-458	-446	-448	-374
Debt-free Net Working Capital (DFNWC)	-301	-75	-8.76	-121	-212	-331	-400	-419	-399	-420	-343
Net Working Capital (NWC)	-301	-75	-8.76	-121	-212	-331	-400	-474	-514	-470	-483
Net Nonoperating Expense (NNE)	-4.51	-7.43	-5.28	-4.26	-7.93	-2.92	1.45	2.14	0.15	2.60	-3.28
Net Nonoperating Obligations (NNO)	-441	-669	-657	-511	-407	-245	-95	16	68	22	109
Total Depreciation and Amortization (D&A)	6.93	13	25	7.24	6.99	6.97	6.88	6.52	5.96	5.90	5.79
Debt-free, Cash-free Net Working Capital to Revenue	-34.42%	-35.31%	-32.14%	-31.11%	-31.52%	-30.58%	-27.78%	-27.36%	-28.54%	-30.67%	-27.24%
Debt-free Net Working Capital to Revenue	-13.95%	-3.57%	-0.42%	-5.94%	-10.79%	-17.57%	-22.43%	-25.02%	-25.54%	-28.73%	-24.99%
Net Working Capital to Revenue	-13.95%	-3.57%	-0.42%	-5.94%	-10.79%	-17.57%	-22.43%	-28.31%	-32.90%	-32.16%	-35.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.77	$3.78	$3.11	$2.85	$3.32	$2.55	$2.30	$2.00	$2.35	$2.17	$2.13
Adjusted Weighted Average Basic Shares Outstanding	30.39M	30.96M	31.05M	30.99M	30.84M	30.72M	30.63M	30.54M	31.01M	32.39M	31.01M
Adjusted Diluted Earnings per Share	$3.67	$3.67	$3.01	$2.75	$3.20	$2.46	$2.22	$1.93	$2.27	$2.08	$2.05
Adjusted Weighted Average Diluted Shares Outstanding	31.20M	32.01M	32.09M	32.09M	32.00M	31.84M	31.76M	31.58M	32.16M	33.67M	32.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.74M	30.47M	31.08M	31.00M	30.98M	61.52M	61.37M	30.56M	30.50M	31.05M	31.10M
Normalized Net Operating Profit after Tax (NOPAT)	110	110	91	84	95	75	72	63	73	71	63
Normalized NOPAT Margin	19.71%	20.42%	17.09%	15.92%	18.52%	15.12%	14.62%	13.71%	16.83%	18.08%	16.35%
Pre Tax Income Margin	21.16%	24.95%	22.27%	20.92%	22.07%	18.20%	16.89%	16.44%	19.82%	18.69%	21.34%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	130.11%	42.01%	0.00%	0.00%	7.64%	50.92%	69.99%	71.17%	210.95%	345.54%	353.13%

Frequently Asked Questions About Medpace's Financials

When does Medpace's fiscal year end?

According to the most recent income statement we have on file, Medpace's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Medpace's net income changed over the last 9 years?

Medpace's net income appears to be on an upward trend, with a most recent value of $404.39 million in 2024, falling from -$8.67 million in 2015. The previous period was $282.81 million in 2023. See Medpace's forecast for analyst expectations on what’s next for the company.

What is Medpace's operating income?

Medpace's total operating income in 2024 was $446.87 million, based on the following breakdown:

Total Gross Profit: $2.11 billion
Total Operating Expenses: $1.66 billion

How has Medpace revenue changed over the last 9 years?

Over the last 9 years, Medpace's total revenue changed from $359.06 million in 2015 to $2.11 billion in 2024, a change of 487.4%.

How much debt does Medpace have?

Medpace's total liabilities were at $1.28 billion at the end of 2024, a 16.2% increase from 2023, and a 123.5% increase since 2015.

How much cash does Medpace have?

In the past 9 years, Medpace's cash and equivalents has ranged from $0.00 in 2018 to $669.44 million in 2024, and is currently $669.44 million as of their latest financial filing in 2024.

How has Medpace's book value per share changed over the last 9 years?

Over the last 9 years, Medpace's book value per share changed from 13.19 in 2015 to 26.56 in 2024, a change of 101.4%.

Related Companies

This page (NASDAQ:MEDP) was last updated on 5/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Financials

Frequently Asked Questions About Medpace's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Financials

Annual Income Statements for Medpace

Quarterly Income Statements for Medpace

Annual Cash Flow Statements for Medpace

Quarterly Cash Flow Statements for Medpace

Annual Balance Sheets for Medpace

Quarterly Balance Sheets for Medpace

Annual Metrics And Ratios for Medpace

Quarterly Metrics And Ratios for Medpace

Frequently Asked Questions About Medpace's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools